CN116270575A - Pharmaceutical composition and patch containing flurbiprofen - Google Patents
Pharmaceutical composition and patch containing flurbiprofen Download PDFInfo
- Publication number
- CN116270575A CN116270575A CN202310287597.1A CN202310287597A CN116270575A CN 116270575 A CN116270575 A CN 116270575A CN 202310287597 A CN202310287597 A CN 202310287597A CN 116270575 A CN116270575 A CN 116270575A
- Authority
- CN
- China
- Prior art keywords
- flurbiprofen
- weight
- parts
- patch
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 229960002390 flurbiprofen Drugs 0.000 title claims abstract description 76
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 239000010410 layer Substances 0.000 claims description 27
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- 239000011347 resin Substances 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 17
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 14
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 14
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 14
- 229920001983 poloxamer Polymers 0.000 claims description 13
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 12
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 12
- 229920002367 Polyisobutene Polymers 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229960000502 poloxamer Drugs 0.000 claims description 12
- 150000003505 terpenes Chemical class 0.000 claims description 12
- 235000007586 terpenes Nutrition 0.000 claims description 12
- 229940057995 liquid paraffin Drugs 0.000 claims description 11
- 239000008247 solid mixture Substances 0.000 claims description 11
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 10
- 239000000920 calcium hydroxide Substances 0.000 claims description 10
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 8
- 230000008961 swelling Effects 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000007599 discharging Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000005456 glyceride group Chemical group 0.000 claims 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 abstract description 28
- 239000000463 material Substances 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 239000011159 matrix material Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000000945 filler Substances 0.000 description 11
- 239000003961 penetration enhancing agent Substances 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 239000004014 plasticizer Substances 0.000 description 9
- 229910000831 Steel Inorganic materials 0.000 description 8
- 239000010959 steel Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 7
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 7
- 102100028292 Aladin Human genes 0.000 description 6
- 101710065039 Aladin Proteins 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000016247 Soft tissue disease Diseases 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- -1 glycerol ester Chemical class 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012943 hotmelt Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000037317 transdermal delivery Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 230000005496 eutectics Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920006267 polyester film Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000013271 transdermal drug delivery Methods 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002318 adhesion promoter Substances 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000011874 heated mixture Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229920006132 styrene block copolymer Polymers 0.000 description 2
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 2
- 150000003440 styrenes Chemical class 0.000 description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 125000001755 (-)-menthol group Chemical group 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229920005987 OPPANOL® Polymers 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920006465 Styrenic thermoplastic elastomer Polymers 0.000 description 1
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000379 polypropylene carbonate Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910021487 silica fume Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000004520 water soluble gel Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition containing flurbiprofen, which contains flurbiprofen and pharmaceutically acceptable auxiliary materials as active ingredients, wherein the pharmaceutically acceptable auxiliary materials at least contain a stabilizer, the weight ratio of the flurbiprofen to the stabilizer is 1 (0.5-2), and the components of the flurbiprofen contained in the pharmaceutical composition containing the flurbiprofen can be mutually matched, so that the pharmaceutical composition containing the flurbiprofen has the characteristics of good stability of the active ingredients and excellent transdermal absorption performance.
Description
Technical Field
The invention belongs to the field of pharmaceutical preparations, and in particular relates to a pharmaceutical composition and a patch containing flurbiprofen.
Background
Flurbiprofen is a propionic acid non-steroidal anti-inflammatory drug (NSAIDs) which plays a role in treatment mainly by inhibiting prostaglandin synthetase, has better analgesic and anti-inflammatory effects, is clinically used for symptomatic treatment of inflammation, fever and mild-moderate pain, and can be used for treating patients with ineffective or intolerance of aspirin.
The products containing flurbiprofen which are currently sold in the market comprise tablets, granules, injections, external preparations and the like. The flurbiprofen oral preparation is rapid to absorb, but has a short biological half-life in vivo, which is only 3-5 hours, and frequent administration is needed in the long-term rheumatoid arthritis treatment process, so that the aim of long-term treatment cannot be fulfilled. Secondly, oral flurbiprofen is prone to gastrointestinal adverse reactions, such as peptic ulcer and hemorrhage, which cause that part of patients cannot use the oral flurbiprofen.
Compared with flurbiprofen oral preparation, the transdermal administration can effectively avoid adverse reactions of gastrointestinal tracts, prolong the acting time of the medicine, reduce the administration times and improve the compliance of patients. Transdermal administration is therefore the preferred mode of flurbiprofen. For example, patent document CN104546803a discloses a preparation method of flurbiprofen hydrogel plaster, in which clomiphene is used as a solubilizer, and the drug is dispersed in a hydrophilic polymer material matrix. Similarly, patent CN1443532a disperses flurbiprofen in a hydrophilic cataplasm matrix by an emulsifier, and patent CN106822065A stabilizes the drug in a hydrophilic matrix material by adding an additional oil phase such as glyceryl decanoate or the like. However, flurbiprofen is poorly soluble in water and is often added to the hydrophilic matrix in the form of an oil-in-water emulsion mixed with a surfactant and water. Therefore, the gel patch preparation using the water-soluble polymer matrix often has the problems of slow absorption speed and unstable release of the active substance, and needs to be continuously improved. In addition, the preparation process of the water-soluble gel plaster is complex, and the pH value of the matrix is required to be strictly controlled (U.S. Pat. No. 5,807,568), so that inconvenience is caused to the production of the preparation.
Numerous attempts have been made in the prior art to make transdermal formulations of other types of matrices, such as CN103211799a which discloses a transdermal formulation employing polyisobutylene and silicone as matrix materials; CN105232496a discloses a preparation method of a coating agent containing flurbiprofen, which adopts chitosan, carbomer, glycerol and the like as matrix materials; CN103079552A uses diethylene glycol monomethyl etherAnd caprylic capric polyethylene glycol glyceride->Permeation therapy with flurbiprofen is performed by forming a pharmaceutical composition. However, the solvent-based pressure-sensitive adhesive is easy to cause the problems of environmental pollution and high energy consumption due to the use of an organic solvent in the preparation process. Emulsion type pressure-sensitive adhesives are also limited to a certain extent due to the slow drying speed, and the migration of the emulsifier. The Hot Melt Pressure Sensitive Adhesive (HMPSA) adopts thermoplastic polymer as matrix, is coated in a molten state, is cooled and hardened at normal temperature, does not use organic solvent in the preparation process, has high automation degree, and is widely applied to the fields of medical treatment, health and the like.
Based on this, several patents report the preparation method of flurbiprofen hot-melt pressure-sensitive adhesive transdermal formulations. Japanese patent laid-open No. 8-319234 discloses a patch composed of a rubber component, a tackifying resin and a softener. However, the release is poor because several binder components do not dissolve flurbiprofen and flurbiprofen is in a crystalline state in the formulation. In order to improve the state of the drug in the matrix, WO93/04677 discloses a method of using L-menthol as a flurbiprofen dissolution agent, however, there is still a possibility of crystallization of flurbiprofen with volatilization of L-menthol. Japanese patent laid-open No. 7-309749 discloses the use of lactate as a dissolving agent, but destroys the cohesive force of the adhesive matrix, and further causes pasty residue on the skin, causing skin irritation. Patent document CN102028673a stabilizes the drug by adjusting the proportion of the tackifying resin in the matrix, thereby inhibiting crystallization of flurbiprofen into the adhesive layer, but the tackifying resin has poor compatibility with the drug, can only prolong the patch stability to about 3 months, has poor patch carrying capacity, can only maintain effective release of the drug for about 8 hours, requires clinical administration three times a day, and is excessively frequent in administration frequency.
Disclosure of Invention
In order to improve the problems existing in the prior art, the present invention provides a pharmaceutical composition comprising flurbiprofen as an active ingredient, and pharmaceutically acceptable excipients, which at least comprise a stabilizer;
the weight ratio of flurbiprofen to the stabilizer is 1 (0.5-2), for example 1 (0.7-1.5), and the weight ratio is 1:0.5, 1:0.75, 1:1, 1:1.2, 1:1.5 or any weight ratio in the range formed by combining any two of the above proportions.
According to an embodiment of the invention, the flurbiprofen is dispersed in the pharmaceutical composition in an amorphous form.
According to an embodiment of the present invention, the stabilizer is a high molecular nonionic surfactant, for example, may be selected from polyoxyethylene polyoxypropylene ether block copolymers (poloxamers; e.g.)) One, two or more of polyvinyl alcohol (PVA) and polyvinylpyrrolidone (PVP for short), preferably poloxacinA mu or polyvinylpyrrolidone, illustratively poloxamer F68 or polyvinylpyrrolidone K-90. According to an embodiment of the present invention, the pharmaceutically acceptable auxiliary materials may further comprise one, two or more of a pressure sensitive adhesive matrix, a tackifier, a plasticizer, a filler, an antioxidant, a permeation enhancer, and the like.
According to the embodiment of the invention, the pressure-sensitive adhesive matrix is a styrene thermoplastic elastomer, and the styrene thermoplastic elastomer means a styrene polymer material which shows rubber elasticity at normal temperature and can be plasticized and molded at high temperature. Preferably, the styrenic thermoplastic elastomer may be selected from one, two or more of styrene-isoprene-styrene block copolymer (SIS), styrene-butadiene-styrene block copolymer (SBS), hydrogenated styrene-ethylene-butadiene-hydrogenated styrene block copolymer (SEBS) and hydrogenated styrene-isoprene-hydrogenated styrene block copolymer (SEPS).
According to embodiments of the present invention, the weight ratio of the pressure sensitive adhesive matrix to flurbiprofen is (1-3): 1, for example (1.5-2.5): 1, and exemplary are 1.2:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, 2.0:1, 2.1:1, 2.2:1, 2.3:1, or any weight ratio in the range of any two-to-two combinations of the foregoing.
According to an embodiment of the present invention, the tackifier may be selected from a natural tackifier and/or a synthetic tackifier, and the synthetic tackifier may be selected from at least one of an aliphatic resin, an aromatic resin, and the like. For example, the tackifier may be selected from one, two or more of rosin, rosin modified, terpene resin, petroleum resin, and phenolic resin; preferably, the tackifier is selected from terpene resins and hydrogenated rosin glycerol esters.
According to an embodiment of the invention, the weight ratio of the tackifier to flurbiprofen is (0.5-2) 1, for example (0.8-1.5) 1, and is exemplified by 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1 or any weight ratio in the range of any two-to-two combinations of the above.
According to an embodiment of the present invention, the plasticizer may be selected from one, two or more of liquid paraffin, low molecular weight polyisobutylene, dibutyl phthalate, tricresyl phosphate, lanolin, white oil and other pharmaceutically acceptable plasticizers, preferably liquid paraffin and/or low molecular weight polyisobutylene. Preferably, the low molecular weight polyisobutylene has a viscosity average molecular weight of 3500 to 100000; for example, may be selected from polyisobutenes having a viscosity average molecular weight of about 40000.
According to an embodiment of the invention, the weight ratio of plasticizer to flurbiprofen is (2-5): 1, for example (2.5-4): 1, exemplary is 2.7:1, 3:1, 3.2:1, 3.5:1, 3.6:1, 3.8:1 or any weight ratio in the range of any two-to-two combinations of the above.
According to an embodiment of the invention, the filler may be selected from fillers commonly used in the art, such as calcium carbonate, preferably light calcium carbonate (CaCO) 3 ) One, two or more of calcium hydroxide, talcum powder, kaolin, titanium dioxide and micro silica gel. The filler is mainly used for improving cohesive strength of the pressure-sensitive adhesive matrix, enhancing toughness and deformation resistance of colloid and improving dispersion state of flurbiprofen serving as an active ingredient.
According to an embodiment of the invention, the weight ratio of filler to flurbiprofen is (0.001-0.006) 1, for example (0.002-0.005) 1, exemplified by 0.0025:1, 0.003:1, 0.0035:1, 0.004:1 or any weight ratio in the range of any two-to-two combinations of the foregoing.
According to an embodiment of the present invention, the antioxidant may be selected from one, two or more of dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA) and Propyl Gallate (PG).
According to an embodiment of the invention, the weight ratio of antioxidant to flurbiprofen is (0.01-0.06): 1, for example (0.02-0.05): 1, exemplified by 0.025:1, 0.03:1, 0.035:1, 0.04:1 or any weight ratio in the range of any two-to-two combinations of the above.
According to an embodiment of the present invention, the penetration enhancer may be selected from one, two or more of L-menthol, 1, 8-cineole and d-limonene. In addition, the permeation enhancer can also act as a cooling agent.
According to an embodiment of the invention, the weight ratio of the penetration enhancer to flurbiprofen is (0.05-1), for example (0.08-0.5): 1, exemplified by 0.1:1, 0.15:1, 0.2:1, 0.3:1 or any weight ratio in the range of any two-to-two combinations of the above.
According to an embodiment of the invention, the pharmaceutical composition comprises the following components: flurbiprofen, a pressure-sensitive adhesive matrix, a tackifier, a plasticizer, a stabilizer, an antioxidant and a permeation enhancer;
preferably, the mass ratio of flurbiprofen to stabilizer is 1 (0.5-2), for example 1 (0.7-1.5), and exemplary is 1:0.5, 1:0.75, 1:1, 1:1.2, 1:1.5. Within this ratio, flurbiprofen and the stabilizer are capable of forming a eutectic solid dispersion at a temperature above 130 ℃.
In the above pharmaceutical composition, the formation of the eutectic solid dispersion allows flurbiprofen to exist in a pressure-sensitive adhesive matrix in an amorphous highly dispersed state, and the stability of flurbiprofen as an active ingredient is improved by the interaction with the pressure-sensitive adhesive matrix.
According to a preferred embodiment of the present invention, the pharmaceutical composition comprises flurbiprofen in a weight ratio of 1 (1-3): 0.5-2): 2-5): 0.5-2: (0.001-0.006): 0.01-0.06): 0.05-1, a pressure sensitive adhesive matrix, a tackifier, a plasticizer, a stabilizer, a filler, an antioxidant and a permeation enhancer;
the stabilizer is selected from poloxamer and/or polyvinylpyrrolidone, and the flurbiprofen is dispersed in an amorphous form;
preferably, the pressure sensitive adhesive matrix is selected from SIS;
preferably, the terpene resin and/or hydrogenated rosin glycerol ester;
preferably, the plasticizer is selected from liquid paraffin and/or low molecular weight polyisobutylene;
preferably, the filler calcium hydroxide;
preferably, the antioxidant is selected from BHT;
preferably, the penetration enhancer is selected from the group consisting of L-menthol.
According to an embodiment of the invention, the pharmaceutical composition is in the form of a paste.
According to an exemplary embodiment of the present invention, the pharmaceutical composition comprises the following raw materials in parts by weight:
according to an exemplary embodiment of the present invention, the pharmaceutical composition comprises the following raw materials in parts by weight:
the invention also provides application of the pharmaceutical composition in preparing a therapeutic pharmaceutical preparation.
According to an embodiment of the invention, the pharmaceutical formulation is a patch, preferably a transdermal patch.
According to an embodiment of the invention, the pharmaceutical formulation is a pharmaceutical formulation for the treatment of inflammation, fever, soft tissue disease and/or mild to moderate pain. Wherein the inflammation is rheumatoid arthritis, osteoarthritis or ankylosing spondylitis; the soft tissue diseases can be sprains and strains, and the light and medium pain can be dysmenorrhea, postoperative pain, toothache and the like.
The invention also provides a patch which comprises the pharmaceutical composition.
According to an embodiment of the invention, the patch comprises a backing layer, a paste layer and a release layer, the paste layer comprising the above pharmaceutical composition.
Preferably, the paste layer is located between the backing layer and the release layer.
Preferably, the paste layer is formed by dispersing a miniature drug reservoir in the pressure sensitive adhesive layer.
Preferably, the mini-drug depot comprises or consists of flurbiprofen and a stabilizer.
According to an embodiment of the present invention, the material of the backing layer may be selected from materials known in the art, such as a polyester-polyethylene composite film, a polyethylene-aluminum-polyester/ethylene-vinyl acetate composite film, a polyester film, a nonwoven fabric, or a stretch cloth.
According to an embodiment of the present invention, the anti-adhesive layer may be selected from films of materials known in the art, such as release films, exemplified by films of polyethylene, polystyrene, polypropylene or polycarbonate.
According to an embodiment of the invention, the patch has a structure substantially as shown in fig. 1.
According to an embodiment of the invention, the patch is a flurbiprofen hot-melt pressure-sensitive adhesive transdermal formulation.
The invention also provides application of the pharmaceutical composition or the pharmaceutical preparation in treating inflammation, fever, soft tissue diseases and/or mild-moderate pain. Wherein the inflammation is rheumatoid arthritis, osteoarthritis or ankylosing spondylitis; the soft tissue diseases can be sprains and strains, and the light and medium pain can be dysmenorrhea, postoperative pain, toothache and the like.
The invention also provides a method for treating inflammation, fever, soft tissue diseases and/or mild to moderate pain by using the pharmaceutical composition or the pharmaceutical preparation, which comprises the step of applying the pharmaceutical composition or the pharmaceutical preparation to a disease position.
The invention also provides a preparation method of the pharmaceutical composition, which comprises the following steps: and mixing the raw material components in the weight ratio to obtain the pharmaceutical composition.
According to an embodiment of the invention, the preparation method comprises the steps of:
(1) Mixing and swelling the pressure-sensitive adhesive matrix and the plasticizer to obtain a swelling mixture;
(2) Adding a tackifier, a penetration enhancer, a filler and an antioxidant into the swelling mixture, and stirring until the mixture is melted;
(3) Heating and mixing flurbiprofen and a stabilizer to form a solid mixture of flurbiprofen and the stabilizer;
(4) And (3) heating and mixing the solid mixture with the material obtained in the step (2), and cooling after the reaction is completed to obtain the pharmaceutical composition.
According to an embodiment of the present invention, the pressure sensitive adhesive matrix, plasticizer, filler, permeation enhancer, antioxidant, adhesion promoter and stabilizer have the choices and weight ratios as shown above.
According to an embodiment of the invention, in step (1), the swelling temperature is 140-170 ℃, for example 150-160 ℃, illustratively 145 ℃, 150 ℃, 155 ℃, 160 ℃, 165 ℃ or any point value within the range of any two values in pairs.
According to an embodiment of the present invention, in the step (1), the swelling time is more than 30min, for example, 30min to 5h, and is exemplified by 30min, 1h, 2h, 3h, 4h, or any point value in the range of any two values in the two-by-two combination.
According to an embodiment of the present invention, in step (2), the adhesion promoter, penetration enhancer, filler and antioxidant are added sequentially to the swelling mixture.
According to an embodiment of the invention, in step (2), the stirring is carried out to a temperature of 140-170 ℃, for example 150-160 ℃, for example 145 ℃, 150 ℃, 155 ℃, 160 ℃, 165 ℃ or any point value within the range of any two values in pairs.
According to an embodiment of the invention, in step (3), the temperature of the heated mixture is not lower than 130 ℃, for example 140-170 ℃, preferably 150-160 ℃, and in an exemplary case 145 ℃, 150 ℃, 155 ℃, 160 ℃, 165 ℃ or any point value within the range of any two values in pairs.
According to an embodiment of the present invention, in step (3), the solid mixture is a eutectic solid dispersion.
According to an embodiment of the invention, in step (4), the temperature of the heated mixture is not lower than 130 ℃, for example 140-170 ℃, preferably 150-160 ℃, and in an exemplary case 145 ℃, 150 ℃, 155 ℃, 160 ℃, 165 ℃ or any point value within the range of any two values in pairs.
According to an embodiment of the present invention, in the step (4), the heating and mixing time is more than 30min, for example, 30min-5h, and exemplified by 30min, 1h, 2h, 3h, 4h, or any point value in the range of any two values in pairs.
According to an embodiment of the present invention, steps (1), (2) and (4) are performed under inert atmosphere or vacuum conditions. For example, the inert atmosphere may be provided by nitrogen or argon.
The invention also provides a preparation method of the medicinal preparation, preferably a patch, comprising a preparation method of the medicinal composition.
According to an embodiment of the present invention, the method for preparing the patch comprises the steps of: the patch is prepared by taking the medicinal composition as a paste layer, and combining the paste layer, a backing layer and an anti-sticking layer.
According to an embodiment of the invention, the paste layer is located between the backing layer and the release layer.
The invention has the beneficial effects that:
the invention provides a pharmaceutical composition of flurbiprofen with amorphous dispersion and mutual matching of components, and a hot-melt pressure-sensitive adhesive transdermal preparation containing the composition has the characteristics of good stability of active ingredients and excellent transdermal absorption performance. Compared with the pressure-sensitive adhesive transdermal patch in the prior art, the invention can not only stabilize the flurbiprofen serving as an active ingredient by adding the stabilizing agent such as poloxamer and the like, avoid the crystallization of the flurbiprofen, but also ensure that the stabilizing agent does not influence the cohesive force of the matrix and meets the medicinal requirement.
The specific advantages are represented in the following three aspects:
(1) The prepared patch has good adhesion with skin and less irritation and allergy;
(2) The stability of the medicine in the matrix and the concentration of the medicine in the matrix are improved by introducing the stabilizer, the storage time and the effective acting time of the patch are prolonged, and the transdermal release and the adhesive property of the patch are not obviously affected by the addition of the stabilizer;
(3) In the production process, an organic solvent is not required, drying equipment is not required after coating, no bubbles appear on the surface of the patch, and the patch is safe, energy-saving and environment-friendly.
Drawings
FIG. 1 is a schematic structural diagram of a flurbiprofen pressure-sensitive adhesive patch according to an embodiment of the present invention;
FIG. 2 is an in vitro transdermal drug delivery profile of the patches of examples 1-4 and comparative example 1;
FIG. 3 is an in vitro transdermal drug delivery profile of the patch of example 1 and the patch of comparative example 2;
FIG. 4 is an in vitro transdermal drug delivery profile of the patch of example 1 and the patch of comparative example 1 after 3 months of placement;
FIG. 5 is a differential caloric scanning profile (DSC) of different patches after 3 months of placement;
fig. 6 is a polarized photomicrograph of the patch (a) of example 1 and the patch (B) of comparative example 1 after 3 months of standing.
Detailed Description
The technical scheme of the invention will be further described in detail below with reference to specific embodiments. It is to be understood that the following examples are illustrative only and are not to be construed as limiting the scope of the invention. All techniques implemented based on the above description of the invention are intended to be included within the scope of the invention.
Unless otherwise indicated, the starting materials and reagents used in the following examples were either commercially available or may be prepared by known methods.
Namely: the external patch of the present invention is a patch in which an adhesive layer is laminated on a support.
Example 1
The flurbiprofen pressure-sensitive adhesive patch provided in this example was composed of a backing (9100 type, japanese vilene corporation), a paste, and a release layer (KL 12 type, japan DYNIC corporation), the composition of the paste being shown in table 1.
TABLE 1
Component and source thereof | Dosage of |
Flurbiprofen (purity over 99.5%, AESICA, uk) | 13.28g |
SIS (Vector 4111, DEXCO in U.S.) | 22.12g |
Polyisobutene (Oppanol B-10, germany BASF) | 6.55g |
Terpene resin (A135, PINOVA) | 9.83g |
Glycerol ester of hydrogenated rosin (HYDROGRAL-G5, french DRT) | 3.28g |
Poloxamer F68 (German BASF) | 6.64g |
L-menthol (USA SIGMA) | 1.64g |
Liquid paraffin (Shanghai aladin) | 36.21g |
Calcium oxide (Shanghai aladin) | 0.04g |
BHT (Germany MERCK) | 0.41g |
Totalizing | 100.00g |
The preparation process comprises the following steps:
(1) Adding SIS, polyisobutene and liquid paraffin into a reaction container, mixing and swelling for more than 30 minutes at 150-160 ℃, wherein the step is carried out under the condition of filling nitrogen or vacuum;
(2) Sequentially adding terpene resin, L-menthol, calcium hydroxide, BHT and hydrogenated rosin glyceride into the mixture obtained in the step (1), and stirring at 150 ℃ until the terpene resin, the L-menthol, the calcium hydroxide, the BHT and the hydrogenated rosin glyceride are molten, wherein the step is carried out under nitrogen filling or vacuum;
(3) Adding flurbiprofen and poloxamer F68 into another reaction vessel, heating to 150 ℃, mixing and stirring to form a solid mixture of flurbiprofen and poloxamer;
(4) Adding the solid mixture obtained in the step (3) into the reaction container in the step (2), and continuously stirring for more than 30 minutes at 150 ℃, wherein the step is carried out under the condition of nitrogen filling or vacuum;
(5) Stopping stirring after the reaction is finished, discharging after the reaction substances are stable, cooling and packaging.
Example 2
The flurbiprofen pressure-sensitive adhesive patch provided in the embodiment consists of a backing, a paste and an anti-mucous membrane, wherein the components of the paste are shown in table 2.
TABLE 2
The preparation process comprises the following steps:
(1) Adding SIS, polyisobutene and liquid paraffin into a reaction container, mixing and swelling for more than 30 minutes at 150-160 ℃, wherein the step is carried out under the condition of filling nitrogen or vacuum;
(2) Sequentially adding terpene resin, L-menthol, calcium hydroxide, BHT and hydrogenated rosin glyceride into the mixture obtained in the step (1), and stirring at 150 ℃ until the terpene resin, the L-menthol, the calcium hydroxide, the BHT and the hydrogenated rosin glyceride are molten, wherein the step is carried out under nitrogen filling or vacuum;
(3) Adding flurbiprofen and poloxamer F68 into another reaction vessel, heating to 150 ℃, mixing and stirring to form a solid mixture of flurbiprofen and poloxamer;
(4) Adding the solid mixture obtained in the step (3) into the reaction container in the step (2), and continuously stirring for more than 30 minutes at 150 ℃, wherein the step is carried out under the condition of nitrogen filling or vacuum;
(5) Stopping stirring after the reaction is finished, discharging after the reaction substances are stable, cooling and packaging.
Example 3
The flurbiprofen pressure-sensitive adhesive patch provided in the embodiment consists of a backing, a paste and an anti-mucous membrane, wherein the components of the paste are shown in table 3.
TABLE 3 Table 3
Component and source thereof | Dosage of |
Flurbiprofen (purity over 99.5%, AESICA, uk) | 13.28g |
SIS (Vector 4111, DEXCO in U.S.) | 22.12g |
Polyisobutene (Oppano lB-10, germany BASF) | 6.55g |
Terpene resin (A135, PINOVA) | 9.83g |
Glycerol ester of hydrogenated rosin (HYDROGRAL-G5, french DRT) | 3.28g |
Polyvinylpyrrolidone K-90 (MERCK Germany) | 6.64g |
L-menthol (USA SIGMA) | 1.64g |
Liquid paraffin (Shanghai aladin) | 36.21g |
Calcium hydroxide (Shanghai aladin) | 0.04g |
BHT (Germany MERCK) | 0.41g |
Totalizing | 100.00g |
The preparation process comprises the following steps:
(1) Adding SIS, polyisobutene and liquid paraffin into a reaction container, mixing and swelling for more than 30 minutes at 150-160 ℃, wherein the step is carried out under the condition of filling nitrogen or vacuum;
(2) Sequentially adding terpene resin, L-menthol, calcium hydroxide, BHT and hydrogenated rosin glyceride into the mixture obtained in the step (1), and stirring at 150 ℃ until the terpene resin, the L-menthol, the calcium hydroxide, the BHT and the hydrogenated rosin glyceride are molten, wherein the step is carried out under nitrogen filling or vacuum;
(3) Adding flurbiprofen and polyvinylpyrrolidone K90 into another reaction container, heating to 150 ℃, mixing and stirring to form a solid mixture of flurbiprofen and polyvinylpyrrolidone K90;
(4) Adding the solid mixture obtained in the step (3) into the reaction container in the step (2), and continuously stirring for more than 30 minutes at 150 ℃, wherein the step is carried out under the condition of nitrogen filling or vacuum;
(5) Stopping stirring after the reaction is finished, discharging after the reaction substances are stable, cooling and packaging.
Example 4
The flurbiprofen pressure-sensitive adhesive patch provided in the embodiment consists of a backing, a paste and an anti-mucous membrane, wherein the components of the paste are shown in table 4.
TABLE 4 Table 4
Component and source thereof | Dosage of |
Flurbiprofen (purity over 99.5%, AESICA, uk) | 13.28g |
SIS (Vector 4111, DEXCO in U.S.) | 20.29g |
Poly (isobutyl)Alkene (Oppano lB-10, germany BASF) | 6.01g |
Terpene resin (A135, PINOVA) | 9.02g |
Glycerol ester of hydrogenated rosin (HYDROGRAL-G5, french DRT) | 3.01g |
Polyvinylpyrrolidone K-90 (MERCK Germany) | 13.28g |
L-menthol (USA SIGMA) | 1.50g |
Liquid paraffin (Shanghai aladin) | 33.21g |
Calcium hydroxide (Shanghai aladin) | 0.04g |
BHT (Germany MERCK) | 0.38g |
Totals to | 100.02g |
The preparation process comprises the following steps:
(1) Adding SIS, polyisobutene and liquid paraffin into a reaction container, mixing and swelling for more than 30 minutes at 150-160 ℃, wherein the step is carried out under the condition of filling nitrogen or vacuum;
(2) Sequentially adding terpene resin, L-menthol, calcium hydroxide, BHT and hydrogenated rosin glyceride into the mixture obtained in the step (1), and stirring at 150 ℃ until the terpene resin, the L-menthol, the calcium hydroxide, the BHT and the hydrogenated rosin glyceride are molten, wherein the step is carried out under nitrogen filling or vacuum;
(3) Adding flurbiprofen and polyvinylpyrrolidone K90 into another reaction container, heating to 150 ℃, mixing and stirring to form a solid mixture of flurbiprofen and polyvinylpyrrolidone K90;
(4) Adding the solid mixture obtained in the step (3) into the reaction container in the step (2), and continuously stirring for more than 30 minutes at 150 ℃, wherein the step is carried out under the condition of nitrogen filling or vacuum;
(5) Stopping stirring after the reaction is finished, discharging after the reaction substances are stable, cooling and packaging.
Comparative example 1
A transdermal patch was different from example 1 in that poloxamer was not added as a stabilizer to the formulation, and the composition of the paste was as shown in Table 5.
TABLE 5
Comparative example 2
A transdermal patch (patch) disclosed in example 2 of patent document CN102028673a has a paste composition shown in table 6.
TABLE 6
Component and source thereof | Dosage of |
Flurbiprofen | 3g |
SIS | 15g |
Rosin resin | 40g |
Liquid paraffin | 40g |
BHT | 2g |
Totalizing | 100g |
Test case
(one) adhesion Performance detection
The adhesion of the patch was examined according to four methods under the four-part 0952 adhesion assay item of the chinese pharmacopoeia 2015.
1. Primary adhesion detection
The primary adhesion detection is specifically performed as follows: before testing, the patch (together with packaging material) should be placed at 18-25deg.C under 40-70% relative humidity for more than 2 hr. The surfaces of the inclined plate and the stainless steel ball are scrubbed by wiping materials dipped with absolute ethyl alcohol, and are carefully scrubbed by clean dust-free cloth, and the inclined plate and the stainless steel ball are repeatedly cleaned for more than 3 times until the surfaces of the inclined plate and the stainless steel ball are clean through visual inspection. And (3) adjusting the inclined plate according to the inclination angle regulated under each variety item, and taking 3 samples to be tested, wherein the adhesive surface is respectively fixed between two scale marks on the inclined plate by using a double-sided adhesive tape, the lower end of the sample to be tested is positioned at the horizontal line-down position of the inclined plate, and the sample to be tested is flatly attached to the plate. The steel balls specified under each variety item are placed on an initial line and fall freely from the top end of the inclined plane. If 3 steel balls stuck by each of the 3 test samples are the largest steel ball number, or 2 steel balls are the largest steel ball number, the other steel ball number is only one number smaller, and the largest steel ball number is taken as a result; if one is the maximum ball number and the other two are only one smaller, three more test sheets should be taken, and 3 steel balls with the maximum ball number can be stuck to the test results.
2. Measurement of holding power
According to a pharmacopoeia regulation method, taking 3 pieces of a test sample, sticking the test sample on the middle parts of a test board and a loading board in a way of being parallel to the longitudinal direction of the board, rolling the test sample back and forth for 3 times by a compression roller, sticking the test sample on the board, rolling the test sample back and forth for three times, sticking the adhesive surface of the test sample on the surface of the test board, standing vertically, hanging a weight with a regulated mass along the length direction of the test sample, and recording the sliding time of the test sample or the displacement distance within a certain time.
3. Determination of peel strength
Fixing the backing of the test sample on a test board by using double-sided adhesive tape, adhering the adhesive surface of the test sample by using a crystallized polyester film, rolling back and forth on the surface of the test sample for three times by using a 2kg press roller, ensuring that no bubbles exist at the adhering position, and storing for 30 minutes at room temperature for carrying out experiments. The polyester film is folded in half by 180 degrees, the free end of the film and the test board are respectively clamped on the tester up and down, and the stripping surface is consistent with the tester line. The tester continuously peeled at a falling rate of 300 mm/min.+ -.10 mm/min, and the peel strength was calculated from the peel curve.
4. Determination of adhesion
And 3 pieces of test sample are taken, cut into pieces with the size of 50mm multiplied by 70mm, the adhesive surface faces upwards, placed on a sample loading module, aligned with scale marks, fixed according to the stipulation, detected by using a tester, and the forward speed of a press roller is 600mm/min and the backward speed is 21mm/min respectively.
The test results are shown in Table 7.
TABLE 7
Sample name | Initial adhesion results | Results of holding adhesion | Peel strength results | Adhesion results |
Example 1 | No. 23 ball | 10min25s | 359±17N/m | 4771±245mN |
Example 2 | 22 # ball | 10min12s | 348±23N/m | 5074±213mN |
Example 3 | No. 23 ball | 9min33s | 292±30N/m | 4659±668mN |
Example 4 | 22 # ball | 10min55s | 321±6N/m | 5007±366mN |
Comparative example 1 | 25 number ball | 10min30s | 335±16N/m | 5077±297mN |
Comparative example 2 | 18 # ball | 8min20s | 311±21N/m | 4777±247mN |
The results in table 7 show that comparative example 1, in which the recipe was adjusted, had better adhesive properties than comparative example 2, and was mainly characterized by improvement of the initial adhesion and holding adhesion of the patch; examples 1-4 containing the stabilizer showed no significant change in adhesion properties (p > 0.05) over comparative example 1, indicating that the addition of the stabilizer did not adversely affect the adhesion properties of the formulation.
(II) in vitro transdermal experiments
1. Skin treatment:
skin ex vivo of suckling pigs: the suckling pigs of 20-30 days old are killed, the skin on the backs of the pigs is peeled off, the skin is prepared into uniform thickness by a dermatome, and the pigs are refrigerated at-80 ℃ for standby. Before use, the solution is naturally thawed under room temperature condition and washed with physiological saline.
2. Transdermal test
Transdermal experiments were performed using a vertical diffusion cell. The transdermal area was 2.83cm 2 The volume of the receiving tank is 6.8mL, the water bath temperature is 37 ℃, the stirring speed is 250r/min, and the receiving solution is PEG 400-physiological saline solution with the volume percentage concentration of 20 percent. The transdermal patches prepared in the examples and the comparative examples were adhered to the skin surface, fixed on a receiving well, and after the receiving medium was replenished to a prescribed height value of the receiving well, a transdermal test was started, 1.0ml of the receiving medium was sampled at regular time, and then an equal amount of fresh receiving liquid at the same temperature was replenished. The concentration of the absorption liquid obtained by sampling was measured by using a high performance liquid phase under the following conditions:
chromatographic column: kromasil 150 x 4.6mm 5 μm, filler: c18;
column temperature: 40 ℃;
flow rate: 1.0ml/min;
ultraviolet detection wavelength: 245nm;
mobile phase: methanol to water to glacial acetic acid (70:30:1);
sample injection amount: 20 μl;
elution mode: isocratic elution.
The results of fig. 2 show that there is no significant difference in the transdermal absorption of examples 1-4 compared to comparative example 1, indicating that the addition of the stabilizer does not negatively affect the transdermal delivery process of the drug; the results of fig. 3 show that the drug release capacity of example 1 after 8 hours is significantly enhanced compared to comparative example 2, indicating that increasing the drug loading of the drug in the patch can extend the duration of action of the patch; the results of fig. 4 show that the transdermal delivery capacity of example 1 containing the stabilizer is significantly higher than that of comparative example 1 after the patch is placed under normal temperature and light-shielding conditions for 3 months, because the main drug component flurbiprofen in comparative example 1 is likely to be converted from an amorphous state to a crystalline state with higher thermodynamic activity, and the transdermal delivery capacity of the drug is reduced. In summary, the examples according to the present invention containing a stabilizer have a higher stability against the crystallization tendency of flurbiprofen as an active ingredient than the comparative examples not according to the present invention and thus maintain the transdermal delivery capacity of flurbiprofen longer.
(III) sample stability detection
Analyzing and measuring with DSCQC200 differential scanning calorimeter, taking 5-10mg of each group of samples stored for more than 3 months at room temperature, precisely weighing, placing into DSC special small crucible, DSC analysis scanning range is 40-200deg.C, and heating rate is 10 deg.C min -1 The scanning environment is nitrogen.
The results are shown in fig. 5, in which it can be seen that examples 1-3 containing the stabilizer have significantly improved stability, and the drug exists in the patch in amorphous form for a long period of time, as shown in the specific data: comparative example 1 and comparative example 2, which did not contain a stabilizer, exhibited a distinct endothermic peak around 110 ℃, indicating that flurbiprofen was present in crystalline form after 3 months of patch placement; examples 1 to 3 containing the stabilizer had no corresponding endothermic peak around 110 ℃, indicating that flurbiprofen as an active ingredient in the patch was still present in the matrix in an amorphous state, and further, the endothermic peak around 50 ℃ in examples 1 and 2 was presumed to be a characteristic endothermic peak of the corresponding poloxamer.
Further, the patch crystallinity was examined by a polarization microscope method, and the results are shown in fig. 6, in which experimental example 1 shows no crystallization after 3 months of standing, and comparative example 1 shows a large amount of crystallization, indicating that the addition of the stabilizer to the patch can effectively prevent the drug from crystallization, thereby preventing the change of the transdermal permeability of the patch.
The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiment. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (7)
1. A pharmaceutical composition comprising:
13.28 parts by weight of flurbiprofen as active ingredient;
20.29 to 22.12 parts by weight of SIS;
6.01 to 6.55 parts by weight of polyisobutene;
9.02 to 9.83 parts by weight of a terpene resin;
3.01 to 3.28 parts by weight of hydrogenated rosin glycerol ether;
6.64 to 13.28 weight portions of poloxamer F68 or polyvinylpyrrolidone K-90;
1.50 to 1.64 parts by weight of L-menthol;
33.21 to 36.21 parts by weight of liquid paraffin;
0.04 parts by weight of calcium hydroxide; and
0.38 to 0.41 part by weight of BHT.
2. A pharmaceutical composition for promoting transdermal release of flurbiprofen active ingredient in a flurbiprofen patch, comprising:
20.29 to 2022.1229 parts by weight of SIS;
6.01 to 6.55 parts by weight of polyisobutene;
9.02 to 9.83 parts by weight of a terpene resin;
3.01 to 3.28 parts by weight of hydrogenated rosin glycerol ether;
6.64 to 13.28 weight portions of poloxamer F68 or polyvinylpyrrolidone K-90;
1.50 to 1.64 parts by weight of L-menthol;
33.21 to 36.21 parts by weight of liquid paraffin;
0.04 parts by weight of calcium hydroxide; and
0.38 to 0.41 part by weight of BHT.
3. A patch comprising the pharmaceutical composition of claim 1.
4. The patch of claim 2, wherein the patch comprises a backing layer, a paste layer, and a release layer, the paste layer comprising the pharmaceutical composition, wherein the paste layer is located between the backing layer and the release layer.
5. A patch according to claim 3, wherein said paste layer is formed of mini-drug reservoirs dispersed in a pressure sensitive adhesive layer.
6. A method for preparing a pharmaceutical formulation, comprising the steps of:
(1) Adding SIS, polyisobutene and liquid paraffin into a reaction container, mixing and swelling for more than 30 minutes at 150-160 ℃, wherein the step is carried out under the condition of filling nitrogen or vacuum;
4 (2) sequentially adding terpene resin, L-menthol, calcium hydroxide, BHT and hydrogenated rosin glyceride into the mixture obtained in the step (1), and stirring at 150 ℃ until the terpene resin, the L-menthol, the calcium hydroxide, the BHT and the hydrogenated rosin glyceride are melted, wherein the step is carried out under nitrogen or vacuum;
(3) Adding flurbiprofen and poloxamer F68 into another reaction container, heating to 150 ℃, mixing and stirring to form a solid mixture of the flurbiprofen and the poloxamer F68, wherein the mass ratio of the flurbiprofen to the poloxamer F68 is 1:1-2:1;
(4) Adding the solid mixture of flurbiprofen and poloxamer F68 obtained in the step (3) into the reaction vessel in the step (2), and continuously stirring for more than 30 minutes at 150 ℃, wherein the step is carried out under the condition of nitrogen filling or vacuum;
(5) Stopping stirring after the reaction is finished, discharging after the reaction substances are stable, cooling and packaging.
7. A method for preparing a pharmaceutical formulation, comprising the steps of:
(1) Adding SIS, polyisobutene and liquid paraffin into a reaction container, mixing and swelling for more than 30 minutes at 150-160 ℃, wherein the step is carried out under the condition of filling nitrogen or vacuum;
4 (2) sequentially adding terpene resin, L-menthol, calcium hydroxide, BHT and hydrogenated rosin glyceride into the mixture obtained in the step (1), and stirring at 150 ℃ until the terpene resin, the L-menthol, the calcium hydroxide, the BHT and the hydrogenated rosin glyceride are melted, wherein the step is carried out under nitrogen or vacuum;
(3) Adding flurbiprofen and polyvinylpyrrolidone K-90 into another reaction container, heating to 150 ℃, mixing and stirring to form a solid mixture of flurbiprofen and polyvinylpyrrolidone K-90, wherein the mass ratio of the flurbiprofen to the polyvinylpyrrolidone K-90 is 1:1-2:1;
(4) Adding the flurbiprofen and polyvinylpyrrolidone K-90 solid mixture obtained in the step (3) into the reaction container in the step (2), and continuously stirring for more than 30 minutes at 150 ℃, wherein the step is carried out under nitrogen filling or vacuum conditions;
(5) Stopping stirring after the reaction is finished, discharging after the reaction substances are stable, cooling and packaging.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310287597.1A CN116270575A (en) | 2021-08-16 | 2021-08-16 | Pharmaceutical composition and patch containing flurbiprofen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310287597.1A CN116270575A (en) | 2021-08-16 | 2021-08-16 | Pharmaceutical composition and patch containing flurbiprofen |
CN202110938206.9A CN113648297B (en) | 2021-08-16 | 2021-08-16 | Pharmaceutical composition and patch containing flurbiprofen |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110938206.9A Division CN113648297B (en) | 2021-08-16 | 2021-08-16 | Pharmaceutical composition and patch containing flurbiprofen |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116270575A true CN116270575A (en) | 2023-06-23 |
Family
ID=78479296
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310287597.1A Pending CN116270575A (en) | 2021-08-16 | 2021-08-16 | Pharmaceutical composition and patch containing flurbiprofen |
CN202110938206.9A Active CN113648297B (en) | 2021-08-16 | 2021-08-16 | Pharmaceutical composition and patch containing flurbiprofen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110938206.9A Active CN113648297B (en) | 2021-08-16 | 2021-08-16 | Pharmaceutical composition and patch containing flurbiprofen |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN116270575A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115192552B (en) * | 2022-07-15 | 2023-04-21 | 新领医药技术(深圳)有限公司 | Traditional Chinese medicine transdermal patch for effectively relieving rheumatalgia and preparation method thereof |
CN116459238B (en) * | 2023-05-08 | 2023-12-05 | 乐明药业(苏州)有限公司 | Composition for promoting sustained release of glucosamine and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1422097A (en) * | 1995-12-22 | 1997-07-17 | Minnesota Mining And Manufacturing Company | Transdermal device for the delivery of flurbiprofen |
CN1387842A (en) * | 2002-06-19 | 2003-01-01 | 中国人民解放军第二军医大学 | Transdermal plaster of aryl propionic non-steroid antiphlogistic |
CN102099020A (en) * | 2008-05-30 | 2011-06-15 | 迈兰股份有限公司 | Stabilized transdermal drug delivery system |
CN103211799A (en) * | 2013-03-11 | 2013-07-24 | 无锡艾德美特生物科技有限公司 | Flurbiprofen paracetamol ester external use slow release transdermal patch and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102000043B (en) * | 2010-11-19 | 2013-11-06 | 沈阳药科大学 | Flurbiprofen salt transdermal patch and preparation method thereof |
CN112891324A (en) * | 2021-01-19 | 2021-06-04 | 北京亚宝生物药业有限公司 | Transdermal patch |
-
2021
- 2021-08-16 CN CN202310287597.1A patent/CN116270575A/en active Pending
- 2021-08-16 CN CN202110938206.9A patent/CN113648297B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1422097A (en) * | 1995-12-22 | 1997-07-17 | Minnesota Mining And Manufacturing Company | Transdermal device for the delivery of flurbiprofen |
CN1387842A (en) * | 2002-06-19 | 2003-01-01 | 中国人民解放军第二军医大学 | Transdermal plaster of aryl propionic non-steroid antiphlogistic |
CN102099020A (en) * | 2008-05-30 | 2011-06-15 | 迈兰股份有限公司 | Stabilized transdermal drug delivery system |
CN103211799A (en) * | 2013-03-11 | 2013-07-24 | 无锡艾德美特生物科技有限公司 | Flurbiprofen paracetamol ester external use slow release transdermal patch and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
GIL, H.-J.,等: ""Release of flurbiprofen from poloxamer 407 gel"", 《 ARCHIVES OF PHARMACAL RESEARCH》, vol. 17, no. 4, 31 December 1994 (1994-12-31), pages 240 - 243 * |
钟延强,等: ""新型非甾体抗炎药—氟比洛芬制剂学研究进展"", 《药学实践杂志》, vol. 17, no. 02, 31 December 1999 (1999-12-31), pages 33 - 37 * |
Also Published As
Publication number | Publication date |
---|---|
CN113648297B (en) | 2023-07-14 |
CN113648297A (en) | 2021-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2308480B1 (en) | High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications | |
KR960005142B1 (en) | Therapeutic transdermal system containing tulobuterol as the active ingredient | |
CN113648297B (en) | Pharmaceutical composition and patch containing flurbiprofen | |
US20070134310A1 (en) | Transdermal risperidone delivery system | |
US20070098772A1 (en) | Transdermal norelgestromin delivery system | |
US20120034292A1 (en) | Composition For Transdermal Delivery Of Fentanyl | |
US20070104771A1 (en) | Transdermal galantamine delivery system | |
JP2849950B2 (en) | Transdermal formulation | |
KR20150036479A (en) | Patch | |
JP5706324B2 (en) | Fentanyl-containing external patch | |
EP2491924B1 (en) | Water-based paste containing diclofenac sodium | |
WO2024188365A1 (en) | Transdermal patch comprising ransagiline mesylate and preparation method therefor | |
US20030133970A1 (en) | Occlusive transdermal therapeutic system with a non-occlusive backing layer | |
JP5164394B2 (en) | Nicotine sustained-release patch | |
WO2012090322A1 (en) | Patch | |
TWI844643B (en) | A pharmaceutical composition that has excellent absorption by the organism and excellent chemical stability | |
EP2246054B1 (en) | Fentanyl-containing patch for external use | |
JPS62230715A (en) | Novel plaster preparation | |
CN109481423B (en) | Diclofenac salt transdermal patch and preparation method thereof | |
US20200375915A1 (en) | Matrix adhesive patch and process for the preparation thereof | |
EP1338276B1 (en) | Adhesive preparation for external use | |
CN109806243B (en) | A skin external patch containing flupirtine or its medicinal salt | |
JP2647222B2 (en) | Transdermal formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |